Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia Study to the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IASO-782 in Patient With Autoimmune Hematological Diseases (Autoimmune Thrombocytopenia and Warm Antibody Type Autoimmune Hemolytic Anemia)

NCT06534021 is registered in ClinicalTrials.gov with Shanghai IASO Biotechnology Co., Ltd as lead sponsor.

NCT NCT06534021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06534021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia Study to the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IASO-782 in Patient With Autoimmune Hematological Diseases (Autoimmune Thrombocytopenia and Warm Antibody Type Autoimmune Hemolytic Anemia)
Lead sponsor
Shanghai IASO Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
August 8, 2024
Completion date
December 31, 2027
Enrollment
16 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune thrombocytopenia, warm autoimmune haemolytic anaemia